The XRCC5 antibody targets the XRCC5 protein, also known as Ku80. a critical component of the non-homologous end joining (NHEJ) pathway for DNA double-strand break (DSB) repair. Encoded by the XRCC5 gene, Ku80 forms a heterodimer with Ku70 (XRCC6) to form the Ku complex, which binds to broken DNA ends and recruits downstream repair factors, including DNA-PKcs (PRKDC), to initiate repair. This pathway is essential for maintaining genomic stability, V(D)J recombination in immune cells, and telomere maintenance. Dysregulation of XRCC5 is linked to cancer progression, immunodeficiency, and autoimmune disorders.
XRCC5 antibodies are widely used in research to study DNA repair mechanisms, cellular responses to genotoxic stress (e.g., radiation or chemotherapy), and cancer biology. They enable detection of Ku80 expression levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence, providing insights into its role in tumor resistance to DNA-damaging therapies. Additionally, these antibodies help investigate Ku80's involvement in aging, neurodegenerative diseases, and immune system development. Commercial XRCC5 antibodies are typically validated for specificity and application compatibility, ensuring reliability in experimental models ranging from cell lines to clinical tissue samples.